Marco Kesting
Overview
Explore the profile of Marco Kesting including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
658
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiltfang J, Hoffmann J, Schliephake H, Kesting M, Al-Nawas B, Lethaus B
J Craniomaxillofac Surg
. 2025 Jan;
53(4):361-362.
PMID: 39809615
No abstract available.
2.
Foerster Y, Kesting M, Reinauer F, Aksu A, Preidl R
J Maxillofac Oral Surg
. 2024 Dec;
23(6):1646-1652.
PMID: 39618457
Purpose: Despite there being different materials for orbital floor reconstruction available today, outcomes are still not satisfying. In recent years, ultra-high molecular weight polyethylene (UHMWPE) has gained popularity in the...
3.
Schubert H, Matta R, Seidel A, Adler W, Wichmann M, Kesting M, et al.
BMC Oral Health
. 2024 Nov;
24(1):1448.
PMID: 39609793
Background: In order to successfully perform orthodontic mini-implant procedures successfully for the subsequent anchoring of orthodontic appliances, it is crucial to know the palatal bone thickness. This is usually assessed...
4.
Donaubauer A, Frey B, Weber M, Allner M, Vogl C, Almajali O, et al.
Front Oncol
. 2024 Sep;
14:1451035.
PMID: 39346733
The approval and effectiveness of immune checkpoint inhibitors in head-and-neck squamous cell carcinoma (HNSCC) highlights the role of the immune system in this tumor entity. HNSCCs not only interacts with...
5.
Winter L, Ries J, Vogl C, Trumet L, Geppert C, Lutz R, et al.
Cells
. 2024 Sep;
13(18.
PMID: 39329753
The establishment of immunotherapy applying immune checkpoint inhibitors (ICI) has provided an important new option for the treatment of solid malignant diseases. However, different tumor entities show dramatically different responses...
6.
Neurath N, Kesting M
Front Immunol
. 2024 Sep;
15:1435054.
PMID: 39253090
Chronic inflammatory processes in the oral mucosa and periodontitis are common disorders caused by microflora and microbial biofilms. These factors activate both the innate and adaptive immune systems, leading to...
7.
Haderlein M, von der Grun J, Balermpas P, Rodel C, Hautmann M, Steger F, et al.
Front Oncol
. 2024 Sep;
14:1447123.
PMID: 39224800
Background: Current standard treatment concepts in head and neck squamous cell carcinoma (HNSCC) are based on former studies using 2D and 3D treatment plans. However, modern radiation techniques allow for...
8.
Fehlhofer J, Ries J, Nickel F, Rothhammer V, Schwab S, Kesting M, et al.
Life (Basel)
. 2024 Aug;
14(8).
PMID: 39202793
[...].
9.
Ries J, Trumet L, Hahn A, Kunater L, Lutz R, Geppert C, et al.
Int J Mol Sci
. 2024 Jun;
25(12).
PMID: 38928307
In oral squamous cell carcinoma (OSCC) tissues, an immunotolerant situation triggered by immune checkpoints (ICPs) can be observed. Immune checkpoint inhibitors (ICIs) against the PD1/PD-L axis are used with impressive...
10.
Vinayahalingam S, Van Nistelrooij N, Rothweiler R, Tel A, Verhoeven T, Troltzsch D, et al.
Clin Oral Investig
. 2024 Jun;
28(7):364.
PMID: 38849649
Objectives: Diagnosing oral potentially malignant disorders (OPMD) is critical to prevent oral cancer. This study aims to automatically detect and classify the most common pre-malignant oral lesions, such as leukoplakia...